A phase I and pharmacologic study of DMP 840 administered by 24-hour infusion

Annals of Oncology

Volumn 9, Issue 1, 1998, Pages 101-104

  O'Reilly, S ^a   Baker, S D ^a,b   Sartorius, S ^a   Rowinsky, E K ^a,b   Finizio, M ^c   Lubiniecki, G M ^a   Grochow, L B ^a   Gray, J E ^c   Pieniaszek Jr , H J ^c   Donehower, R C ^a  

^a JOHNS HOPKINS UNIVERSITY   (United States)

^b CTRC Institute for Drug Development   (United States)

^c DUPONT COMPANY   (United States)

Author keywords

DMP 840; Pharmacodynamics; Pharmacokinetics; Phase I

Indexed keywords

BISNAFIDE MESYLATE;

ADULT; AGED; ARTICLE; BONE MARROW TOXICITY; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTINUOUS INFUSION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG CLEARANCE; DRUG EFFICACY; DRUG HALF LIFE; DRUG SAFETY; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; NEUTROPENIA; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; SOLID TUMOR; STOMATITIS; THROMBOCYTOPENIA;

EID: 6844252261     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1008260515869     Document Type: Article

References (12)

1. Kirshenbaum MR, Chen SF, Behrens CH et al. (R,R)-2,2′-[1,2-Ethanediylbis{imino(1-methyl-2,l-ethanediyl)]]-bis[5- nitro-1H-benz[de]isoquinoline-1,3-(2H)-dione] Dimethanesulfonate (DMP840), a novel bisnaphthalimide with potent but non-selective tumoricidal activity in vitro. Cancer Res 1994; 54: 2199-2206.
2. Cobb PW, Degen DR, Clark GM et al. Activity of DMP-840, a new bisnaphthalimide, on primary human tumor colony forming units. J Natl Cancer Inst 1994; 86: 1462-5.
3. Maroun J, Steward D, Goel R et al. Phase I Pharmacokinetic study of DMP 840 given in a 3 weekly dosage in a 5 weeks schedule. Proc Am Soc Clin Oncol 1994; 13: 151.
4. Cobb P, Burris H, Finizio M et al. Phase I trial and Pharmacokinetic study of a new bisnaphthalimide, DMP 840. Proc Am Soc Clin Oncol 1994; 13: 159.
5. Slichenmyer W, Finizio M, Sartorius S et al. Phase I and pharmacologic study of DMP 840 as a single infusion every three weeks. Proc Am Soc Clin Oncol 1994; 13: 142.
6. National Cancer Institute. Guidelines for Reporting Adverse Drug Reactions. Bethesda MD: Division of Cancer Treatment Diagnosis and Centers, National Cancer Institute 1988.
7. Woodward HQ, Holodny A. A summary of the data of Mechanik on the distribution of human bone marrow. Phys Med Biol 1960; 5: 57-9.
8. Lai CM, Garner D, Gray JE et al. Determination of bisnafide, a novel bis-naphthalimide anticancer agent, in human plasma and urine by high performance liquid chromatography with UV detection. J Pharm Biomed Anal (in press).
9. D'Argenio DZ, Schumitzky A. ADAPT II User's Guide: Pharmacokinetic/Pharmacodynamic Systems Analysis Software. Los Angeles, CA: Biomedical Simulations Resource 1997.
10. Steimer JL, Mallet A, Golmard JL, Boisvieux JF. Alternative approaches to estimation of population pharmacokinetic parameters: Comparison with non-linear mixed effect model. Drug Metab Rev 1984; 15: 265-92.
11. Hurwitz HI, Grunberg SM. Cobb P et al. A phase II trial of DMP 840 in 5-FU refractory advanced colorectal cancer. Proc Am Assoc Cancer Res 1996; 37: 170.
12. Kline RC, Melnychuk D, Schiano M et al. A phase II multicenter clinical trial of bisnafide in women with advanced refractory ovarian carcinoma. Proc Am Soc Clin Oncol 1996; 15: 293.